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Abstract
Nuts are rich in many nutrients that can benefit multiple cardiometabolic functions, including arterial compliance, blood pressure, inflam-
mation, glucoregulation and endothelial vasodilatation. Impaired vasodilatation may contribute to impaired cognitive performance due
to poor cerebral perfusion. The present narrative review examines associations between nut consumption, vascular health and cognitive
function. It includes a systematic search which identified seventy-one epidemiological or intervention studies in which effects of chronic
nut consumption on blood pressure, glucoregulation, endothelial vasodilator function, arterial compliance, inflammatory biomarkers
and cognitive performance were evaluated. Weighted mean changes were estimated where data were available; they indicate that nut
consumption reduces blood pressure and improves glucoregulation, endothelial vasodilator function and inflammation, whilst a limited
number of studies suggest that nut consumption may also improve cognitive performance. Further clinical trials are warranted to explore
relationships between nut consumption, endothelial function and cognitive function.
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Introduction
CVD and cognitive impairment are growing worldwide
health concerns, particularly as populations age(1,2). In
2006, the worldwide prevalence of Alzheimer’s disease
was estimated at 26·6 million and by 2050 this is predicted
to quadruple(3). Increasing evidence suggests that CVD,
the metabolic syndrome, hypertension, obesity and type 2
diabetes are associated with diminished cognitive function-
ing and an increase in all types of dementia(4). These cog-
nitive changes may be mediated through compromises in
the structural and functional integrity of cerebral blood
vessels. Cognitive performance refers collectively to mental
processes including attention, memory, language, problem
solving and decision making. Understanding the mechan-
isms for regulating cognitive functions is important to
reduce the impact of declining cognition in older adults.
Interventions that slow or prevent this condition are
valuable and have become a health priority(5). One of
the mechanisms by which cognitive performance can be
improved and cognitive decline delayed may be through
maintenance of blood vessel health and improvement in
blood flow to the brain(6,7). Impaired vasodilatation con-
tributes to reduced cognitive performance, due to poor
peripheral and cerebral perfusion(8). Endothelial cells line
blood vessels (including those in the brain); thus maintain-
ing cerebral vascular function to ensure normal regulation
of cerebral blood flow for the delivery of nutrients is essen-
tial to maintain endothelial cell integrity(9).
It has been hypothesised that inflammation may con-
tribute to cognitive decline(10) and to CVD processes(11).
This may be a result of endothelial dysfunction(12,13) associ-
ated with reduced NO bioavailability. NO is an important
vasodilator, produced from L-arginine by endothelial NO
synthase(14). Early phases of atherosclerosis involve the
adhesion of circulating monocytes to the endothelium
(inner lining of blood vessel walls) and their migration
to the intima layer. This is a complex disease process
mediated by inflammatory responses that involve cytokine
production and up-regulation of adhesion molecules such
as intercellular adhesion molecule-1 (ICAM-1), vascular cell
adhesion molecule-1 (VCAM-1) and E-selectin. An increase
in inflammatory cytokines (for example, C-reactive protein
(CRP) and IL-6) have been found to be independent pre-
dictors of CVD and type 2 diabetes(15). The endothelium
is crucial for the maintenance of vascular tone and vascular
structure; endothelial dysfunction predisposes individuals
to complications of atherosclerosis by increasing blood
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pressure and arterial stiffness, characterised by increased
pulse-wave velocity and an increase in augmentation index.
Endothelial function declines with age but is also adversely
affected by hypertension, hyperglycaemia, dyslipidaemia
and obesity, individually or collectively known as the
metabolic syndrome(16).
The principal energy source for the brain is glucose,
which must be supplied continuously due to a limited
storage capacity(17). In addition, a range of nutrients and
substrates including oxygen needs to be delivered via the
blood(18); hence cerebral blood flow and substrate trans-
port across the blood–brain barrier are primary determi-
nants of brain function(19). There is a growing interest in
the role of nutrition in the causation and prevention of
age-related cognitive decline and dementia; more research
is needed to understand mechanisms for cognitive decline
and possible delay.
As shown in Table 1, nuts contain a range of nutrients
with potential health benefits including improved glucose
control and insulin sensitivity(20,21). Despite the high fat
content of nuts, nut consumption has not been shown to
increase body weight; instead it is associated with
improved weight control(15,22). There is a substantial
body of evidence demonstrating lipid-lowering effects of
nut consumption(23) and large epidemiological studies
have consistently revealed an association between frequent
nut consumption and reduced incidence of CHD(24).
A meta-analysis of thirteen intervention studies using
walnuts(25) and a pooled analysis of twenty-five interven-
tion studies with a range of nuts indicated a consistent
cholesterol-lowering effect(26). The analysis in the latter
review revealed a 7·4 % reduction in LDL-cholesterol with
a mean nut consumption of 67 g/d. Reductions in
LDL-cholesterol were dose dependent, but not dependent
on the type of nut consumed(26). The lipid-lowering effects
may be attributed to the high content of unsaturated fat
and fibre in nuts. Other bioactive nutrients in nuts may
benefit glucoregulation(27), endothelial function, blood
pressure control(28) and inflammation(21). Studies have
demonstrated that higher nut consumers are at a signifi-
cantly lower risk of non-cardiovascular inflammatory
disease mortality(29) and risk of developing type 2
diabetes(30) than low nut consumers. These benefits may
be attributed to their nutrient profile; plant-derived n-3
fatty acids (a-linolenic acid; ALA) found in walnuts have
been shown in clinical and epidemiological studies to
improve inflammation, arterial compliance, insulin resist-
ance, endothelial function and blood pressure(31–34).
Nuts, especially consumed with their skin intact, have a sig-
nificant amount of polyphenols(35). The results of many
epidemiological studies suggest that the intake of polyphe-
nol-rich foods has a beneficial effect on a large number of
cardiovascular risk factors including high blood pressure
and poor vascular function(36). Polyphenols and vitamin
E may have a role in modifying some of the inflammatory
mediators(37,38) and be beneficial for cognitive perform-
ance(39,40). Unsalted nuts contain high levels of K and
Mg, making them a potential food for blood pressure con-
trol. However, nuts are commonly sold as a highly salted
product and in this form can substantially increase the
intake of Na, hence reducing their potential benefit. In
addition, nuts contain fibre and L-arginine that has been
shown to improve endothelial function(41–44). Studies
have investigated the impact of nuts on endothelial func-
tion(28); however, no study has taken the next step and
considered whether nuts may have beneficial effects on
Table 1. Nutritional composition of nuts (per 100 g)
Nutrient Almonds Brazils Cashews Hazelnuts Macadamias Pecans Groundnuts Pistachios Walnuts
Energy (kJ)* 2432 2755 2323 2639 3015 2902 2381 2360 2747
SFA (g)* 4 15 8 4 12 7 7 6 6
MUFA (g)* 32 25 24 46 59 40 24 24 9
PUFA (g)* 12 21 8 8 2 21 16 14 47
a-Linolenic acid (g)* 0·0 0·2 0·2 0·1 0·1 0·6 0·0 0·0 6·0
Protein (g)* 21 14 18 17 8 9 25 20 15
Arginine (g)* 2·5 2·2 2·0 2·2 1·2 3·0 1·2 2·2 2·3
Fibre (g)* 13 9 3 10 9 10 9 10 7
Total vitamin E (mg)† 27 4 1 33 1 4 8 7 6
Na (mg)* 1 3 12 0 5 0 18 1 2
K (mg)* 733 659 660 680 368 410 705 1025 441
Mg (mg)* 270 376 292 163 130 121 168 121 158
Anthocyanins (mg)‡ 184 0 9 501 0 494 16 237 67
Flavonoids (mg)§ 40 29 42 14 9 639 146 87 535
Resveratrol (mg)k N/A N/A N/A N/A N/A N/A 102 117 N/A
Total antioxidant
content (with pellicle){
0·41 0·25 0·39 0·71 0·42 8·3 2·0 1·3 23·1
N/A, not available.
* Data from US Department of Agriculture, Agricultural Research Service(140).
† Data from Kornsteiner et al.(141).
‡ Data from Bolling et al.(35).
§ Data from Yang et al.(142).
kData from Tokus¸oglu et al.(143).
{Data from Blomhoff et al.(144).
J. A. Barbour et al.132
N
ut
ri
tio
n 
R
es
ea
rc
h 
R
ev
ie
w
s
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0954422414000079
Downloaded from https:/www.cambridge.org/core. University of Southern Queensland, on 05 Jun 2017 at 00:00:53, subject to the Cambridge Core terms of use, available at
cerebral vascular function and little research has been
conducted on the impact of nut consumption on cognitive
performance.
Thus, unsalted nuts contain the precursor, key ingredi-
ents for cardiometabolic benefits needed to enhance
blood vessel health, which may in turn improve cognitive
function and limit cognitive decline as proposed in Fig. 1.
Using a systematic search protocol, we reviewed the
evidence for the effects of both tree and ground nuts
on glucoregulation, blood pressure, arterial compliance,
inflammation, endothelial vasodilator function and cog-
nitive performance. As noted previously, there is a large
body of consistent evidence demonstrating improvements
in lipid regulation with nut consumption(25,26); hence this
component has not been included in the present review.
Methods
Selection of studies
Medline (via Ovid) and CINAHL (via Ebsco host) databases
and the Cochrane Library were searched on 21 November
2012. Search terms used included MeSH (Medical Subject
Headings) terms: ‘nuts’ OR ‘almond*’ OR ‘Brazil nut*’ OR
‘cashew*’ OR ‘hazelnut*’ OR ‘macadamia*’ OR ‘peanut*’
OR ‘pecan*’ OR ‘pistachio*’ OR ‘walnut*’ AND ‘endothel*’
OR ‘FMD’ OR ‘vascular*’ OR ‘blood pressure’ OR ‘arterial
compliance’ OR ‘vasodilatation’ OR ‘glucose’ OR ‘insulin’
OR ‘inflam*’ OR ‘cognit*’. Limits included ‘human only’
and ‘English language’. In addition, reference lists from
the publications identified by the database searches were
also manually searched to identify other relevant articles
that were not detected by the searches. Studies were
included if they met the following criteria: intervention or
epidemiological studies in human subjects. Intervention
diets included at least one of the following nuts: almonds,
cashews, hazelnuts, macadamias, groundnuts, pistachios,
walnuts, pecans or Brazil nuts. Intervention studies
included assessment of chronic nut consumption for a
minimum period of 3 weeks, thereby assessing chronic
changes. Published studies were required to be original
research and evaluate the effects of nuts on at least one
of the following in human subjects: glucoregulation, endo-
thelial vasodilator function, arterial compliance, resting
blood pressure, inflammation or cognitive performance.
Reduced
inflammation
Improved
cognitive
function
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Fig. 1. Summary of potential effects of nutrients in nuts to improve cardiovascular risk factors (lipid profile, arterial compliance, glucoregulation, oxidative stress,
blood pressure and inflammation) and consequent improvement in endothelial function and potential improvement in cerebral vascular function and hence
cognitive performance. ! , Weak evidence; ! , strong evidence; $ , bi-directional effect; $ , strong bi-directional effect.
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Studies were excluded if they were non-English-language
papers, narrative reviews, systematic reviews, expert
opinions, editorials, abstracts, letters to the editor, theses,
or animal or in vitro studies. Weighted mean changes in
glucoregulation, systolic and diastolic blood pressure,
CRP, ICAM-1, VCAM-1 and endothelial vasodilator function
were calculated for studies that reported data suitable
for calculating a percentage change. Study sample size
was used to weight the calculation of the overall mean
percentage change across studies using STATA software
(StataIC 11; StataCorp LP).
Results
The search revealed articles published between March
1993 and October 2013. Of the 4198 articles identified
by all databases and nine articles identified from hand
searching, 3019 were excluded as duplicates, 114 were
excluded because of document type (review, note, letter,
proceedings paper, or meeting abstract) and 837 were
excluded because they did not assess endothelial function,
blood pressure, inflammation, glucoregulation or cognitive
performance in conjunction with nut consumption. Of
the 237 articles screened (titles and abstracts), 166 were
excluded because they did not meet the inclusion criteria.
Therefore, seventy-one studies were included in the present
review as shown in the PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) flowchart
(Fig. 2). A total of forty-four studies evaluated blood pressure,
thirty-two evaluated glucoregulation, thirty-one evaluated
inflammatory markers, nine evaluated endothelial vasodilator
function, two evaluated arterial compliance and four eva-
luated cognitive performance. A total of nine types of nut
were used in these studies: almonds, Brazil nuts, cashews,
hazelnuts, macadamias, groundnuts, pistachios, pecans and
walnuts. The majority of studies examined walnuts, almonds
and mixed/any nuts (Table 2).
Most research measuring the effect of nut consumption
on glucoregulation, blood pressure, inflammation, arterial
compliance, endothelial vasodilator function and cognition
has been performed with walnuts, mixed or non-specified
nuts, almonds and pistachios, with only seven studies
using groundnuts, hazelnuts, cashews, Brazil nuts or maca-
damias and no studies with pecans (Table 2). Studies are
summarised in Tables 3–8 and are grouped according
to outcomes, presented in order of efficacy (using mean
percentage or blood pressure (mmHg) change where avail-
able). The following information was also extracted: author
and year of publication, number, age and sex of the
participants, type of individuals studied (i.e. healthy,
hyperlipidaemic, high CHD risk, type 2 diabetes, over-
weight/obese or metabolic syndrome), study design,
Additional studies
identified with hand
search
Initial bibliographic search
Pool of citations (n 4198)
(Medline n 2845, Embase
n 1097, CINAHL n 190,
Cochrane Library n 66)
Pool of citations (n 9)Pool of citations (n 4207)Identification
Duplicate removal
(n 3019 removed)
Application of inclusion
and exclusion criteria
(n 951 excluded)
Remaining articles after
duplicate removal (n 1188)
Remaining articles (titles and
abstracts) after assessment for
eligibility (n 237)
Screening
Eligibility
Included Final full-text articles includedin analysis (n 71)
Application of inclusion
and exclusion criteria
(n 166 excluded)
Fig. 2. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow chart showing procedures used to identify studies investigating the
effect of nuts on blood pressure, endothelial function, inflammation, arterial compliance, glucoregulation and cognition included in the systematic search.
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length of intervention, type and dose of nut, controls used
and effect-size calculations where possible. Fig. 3 presents
the number of outcome measures and the type of studies
reflecting the level of evidence for these studies according
to National Health and Medical Research Council guide-
lines(45). Most intervention studies were randomised and
controlled, providing greater evidence than uncontrolled
or non-randomised trials.
Effects of nuts on glucoregulation
Details of studies measuring the effect of nut consumption
on glucoregulation are reported in Table 3. A total of eight
observational and twenty-four intervention trials evaluated
the effects of chronic consumption of nuts on gluco-
regulation. Nuts consumed included walnuts, pistachios,
groundnuts, almonds, cashews and mixed nuts, with
amounts consumed ranging from 10 to 108 g/d ( 13 ounce
to 4 ounces) (approximately 2–20 % of energy intake).
The duration of consumption ranged from 4 weeks to
16 years. Intervention studies made comparisons with a
healthy diet (fourteen studies), habitual diet (three studies),
high-fat diet (one study) or other food products (five
studies): muffins, pretzels, cereal bar, cheese or another
type of nut. One study used no control. Of the studies,
four compared habitual or healthy diets with interven-
tion diets including nuts (NORDIET(46) or a Mediterranean
diet(47,48)).
Tree nuts were associated with a lower prevalence of
fasting hyperglycaemia compared with non-nut consumers
in the National Health and Nutrition Survey (NHANES)
cohort study(49). However, a healthy dietary pattern inclu-
ding nuts found no association with fasting glucose or
insulin(50). It is possible that the amount of nuts consumed
was insufficient to show benefits. Nut consumption has
also been associated with a reduced risk of type 2 diabetes;
evidence to support this comes from large epidemiological
studies(51–54). The Nurses’ Health Study demonstrated that
consumption of nuts ($ 5 times per week), peanut butter
($ 5 times per week) or walnuts ($ twice per week) was
associated with a 24, 21 and 15 % lower risk, respectively,
of developing type 2 diabetes(51,54) compared with those
who never or rarely ate nuts; the effect was greatest in
those of healthy body weight(51). In addition, the Shanghai
Women’s Health Study demonstrated that groundnut con-
sumption was associated with a 22 % decreased risk of
type 2 diabetes(55). The SUN Study demonstrated a 35 %
reduced risk of type 2 diabetes with a Mediterranean diet
including an unspecified quantity of nuts(53). However,
other components of the Mediterranean diet including
olive oil and a high fibre intake may have also contributed
to this outcome(56). In contrast, the Iowa Women’s Health
Study did not find any association of consumption of
foods high in vegetable fat (including nuts) and incidence
of type 2 diabetes(57), which may in part be due to the low
mean intake of nuts in this cohort.
Clinical trials examining nut consumption and diabetes
risk, glycaemic control or insulin resistance have suggested
some beneficial effects. Some short-term intervention
studies have shown benefits of nut consumption on
glucose homeostasis(58,59) and insulin secretion(46,58,60,61).
The effects of nuts on insulin sensitivity are influenced
strongly by changes in body weight, which may have
accounted for the changes observed in one of these studies
where participants reduced body weight with nut con-
sumption. Longer intervention trials with Mediterranean
diets supplemented daily with 20–50 g of walnuts or 30 g
of mixed nuts (a mixture of walnuts, almonds and hazel-
nuts was used in the PREvencion con DIeta MEDiterranea
(PREDIMED) trial as reported by Casas-Agustench et al.(21))
resulted in a reduction in fasting glucose, insulin and
improvement in insulin sensitivity (homeostatic model
assessment of insulin resistance; HOMA)(47) and the inci-
dence of type 2 diabetes by 52 % over 4 years(30). Benefits
shown in studies with nuts included as part of the interven-
tion diet (NORDIET(46) or Mediterranean diet(47)) may have
been partly due to other components of these diets(62).
Other studies have not shown benefits; consumption of
pistachios, almonds, walnuts and a Mediterranean diet
(supplemented with 10 g nuts/d) revealed no effect on
Table 2. Number of measures of nut consumption on the effect on blood pressure, glucoregulation, inflammation, arterial
compliance, endothelial function and cognition (some studies tested more than one type of nut)
Nut type Blood pressure Glucoregulation Inflammation
Arterial
compliance
Endothelial
function* Cognition
Walnut 11 9 9 1 4 2
Mixed/any nut 14 12 10 1 2 2
Almond 10 8 8 – – –
Pistachio 3 2 1 – 2 –
Hazelnut 1 1 2 – 1 –
Cashew 1 1 1 – – –
Brazil – – 1 – – –
Macadamia 1 – – – – –
Groundnut 1 1 – – – –
Pecan – – – – – –
Total 42 34 31 2 9 4
* Endothelial vasodilator function assessed by either flow-mediated dilatation or Endo-PAT device.
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Table 3. Studies measuring effect of nut consumption on glucoregulation
Author Time Participants Study design Amount/type of nuts Outcomes†
Effect;
effect size
Observational studies measuring effect of nut consumption on diabetes risk and elevated glucose (studies presented in order of efficacy)
Martı´nez-Gonza´lez
et al. (2008)(53)
4 years n 13380, healthy, M and F,
mean 38 (SD 12) years
Prospective cohort
(SUN study), FFQ
and incidence of Dm
Tertiles of Med diet
(unspecified amount
of nuts)
RR Med diet # 35 % RR
incidence of Dm
þ
1·0
0·41 (95 % CI 0·2, 0·9)
0·17 (95 % CI 0·04, 0·8)
Jiang et al.
(2002)(51)
16 years n 137856, healthy, F,
mean 46 (range 34–59)
years
Prospective cohort
(Nurses’ Health Study),
FFQ and incidence of
Dm
Quantiles of nuts/peanut
butter
RR Nuts # 24 % RR, peanut
butter # 21 % RR
incidence of Dm
þ
Never/rare 1·0
,1 time/week 0·98 (95 % CI 0·9, 1·1)
1–4 times/week
. 5 times/week
0·91 (95 % CI 0·8, 1·0)
0·79 (95 % CI 0·7, 0·8)
Villegas et al.
(2008)(55)
5 years n 64227, healthy, F, mean
49 (range 43–63) years
Prospective cohort
(Shanghai Women’s
Health Study), FFQ and
incidence of Dm
Quintiles of groundnut
consumption
RR Groundnuts # 20 % RR
incidence of Dm
þ
1·0
0·8 (95 % CI 0·7, 0·9)
0·95 (95 % CI 0·82, 1·1)
0·79 (95 % CI 0·7, 0·9)
0·8 (95 % CI 0·7, 0·9)
Pan et al.
(2013)(54)
4 years n 137856, healthy, F,
mean 52 (SD 10) years
Prospective cohort
(Nurses’ Health Study
cohorts 1 and 2), FFQ
and incidence of Dm
Quintiles of walnut
consumption
RR Walnuts # 15 % RR
incidence of Dm
þ
Never/rare 1·0
,1 serve/week 1·01 (95 % CI 0·95, 1·08)
1 serve/week 1·01 (95 % CI 0·90, 1·13)
$2 serves/week 1·04 (95 % CI 0·92, 1·18)
Meyer et al.
(2001)(57)
11 years n 7210, high risk of CVD,
M and F, mean 68
(SD 6) years
X-sect, FFQ, prevalence
of elevated glucose
(PREDIMED)
Quintiles of vegetable fat
(including nuts)
Data N/A No association of
incidence of Dm with
nut consumption
NS-G
Cross-sectional studies measuring effect of nut consumption on diabetes risk and elevated glucose (studies presented in order of efficacy)
Nettleton et al.
(2008)(145)
X-sect n 5011, healthy, M and
F, 45–84 years
X-sect, MESA, FFQ and
prevalence of Dm
Quintiles of healthy dietary
pattern (including any
nuts)
# 15 % RR incidence
of Dm with nut
consumption
þ
O’Neil et al.
(2011)(49)
X-sect n 13 292, general
population, M and
F, 19–50 þ years
X-sect, 1999–2004
NHANES, 24 h recall
and prevalence of
elevated glucose
‘All’ nut group $ 7 g/d (A) No association of
prevalence of elevated
glucose with ‘all’
nut consumption
NS-G
Tree nut group $7 g/d (B) 4 % # prevalence
elevated glucose with
tree nut consumption
þ
Ibarrola-Jurado
et al. (2013)(81)
X-sect n 7210, high risk of CVD,
M and F, mean 68
(SD 6) years
X-sect, FFQ, prevalence
of elevated glucose
(PREDIMED)
Tertiles (any nuts) No association of elevated
glucose with nut
consumption
NS-G
, 28 g/week 1·0
28–84 g/week 0·95 (95 % CI 0·71, 1·29)
. 84 g/week 0·85 (95 % CI 8·81, 1·53)
Intervention studies measuring effect of nut consumption on glucoregulation (studies presented in order of efficacy)
Salas-Salvado´
et al. (2011)(30)
4 years n 418 (control ¼ 134,
nuts ¼ 145, OO ¼ 139)
high risk of CVD, M and
F, mean 68 (range
55–80) years
RCT, parallel, Med diet þ
OO v. Med diet þ nuts
v. LF diet (control)
(PREDIMED)
30 g/d mixed nuts‡ # 52 % RR incidence
of Dm
þ
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Table 3. Continued
Author Time Participants Study design Amount/type of nuts Outcomes†
Effect;
effect size
Esposito et al.
(2004)(47)
2 years n 180 (control ¼ 90, Med
diet ¼ 90), Met-S, M
and F, mean 44 (SD 6)
years
RCT, parallel, Med diet
(including nuts) v.
prudent diet (control)
20–50 g/d walnuts Glucose # 5 %* þ ; 0·8
Insulin # 33 %* þ ; 0·8
HOMA # 45 %* þ ; 0·8
Wien et al.
(2010)(61)
16 weeks n 65 (control ¼ 32, nut
¼ 33), pre-diabetes, M
and F, mean 53 (SD 9)
years
RCT, parallel, American
Diabetes Association
diet (control) with/
without almonds
56 g/d almonds Glucose NS NS-G; 0·2
Insulin # 32 %* þ ; 1·3
HOMA # 40 %* þ ; 0·2
HbA1c NS NS-G; 0·4
Casas-Agustench
et al. (2011)(60)
12 weeks n 50 (control ¼ 25, nut
¼ 25), Met-S, M and F,
mean 52 (SD 8) years
RCT, parallel, isoenergetic
healthy diet (control)
with/without nuts
30 g/d mixed nuts‡ Glucose NS NS-G; 0·0
Insulin # 33 %* þ ; 0·4
HOMA # 33 %* þ ; 0·4
Adamsson et al.
(2011)(46)
4 weeks n 86, M and F (control
¼ 42, NORDIET ¼ 44),
mean 53 (SD 8) years,
hypercholesterolaemic
RCT parallel, NORDIET
(high fibre, fish, LF
dairy, nuts) v. habitual
diet (control)
Ad libitum almonds Glucose NS NS-G; 0·0
Insulin # 24 %* þ ; 0·5
HOMA # 25 %* þ ; 0·6
Sari et al.
(2010)(59)
4 weeks
per arm
n 32, healthy M, mean 22
(range 21–24) years
Prospective cohort,
isoenergetic Med diet
(control) with/without
pistachios, no washout
80–100 g/d pistachios Glucose # 9 % þ ; 0·9
Kalgaonkar et al.
(2011)(62)
6 weeks n 31 (almond ¼ 14,
walnut ¼ 17), F, with
PCOS, age range
20–45 years
Pre-/post-measures
walnuts v. almonds
36 g/d walnuts (W)
26 g/d almonds (A)
Glucose NS (W v. A) NS-G
Insulin NS (W v. A) NS-G; 0·8
HOMA NS (W v. A) NS-G; 2·3
HbA1c # 4 %* (W v. A) þ ; 0·1
Estruch et al.
(2006)(58)
12 weeks n 772 (control ¼ 257, OO
¼ 257, nuts ¼ 258),
high risk of CVD, M and
F, mean 69 (SD 6) years
RCT, parallel, Med diet þ
OO v. Med diet þ nuts
v. LF diet (control)
(PREDIMED)
30 g/d mixed nuts‡ Glucose # * data N/A þ ; 0·1
Insulin # * data N/A þ ; 0·2
HOMA # * data N/A þ ; 0·3
Cohen & Johnston
(2011)(64)
12 weeks n 13 (control ¼ 6, nut
¼ 6), Dm, mean 66
(SD 3) years
Pilot study, RCT, parallel
almonds or cheese
(control)
28 g/d almonds Glucose NS NS-G; 0·3
Insulin NS NS-G; 0·7
HbA1c # 4 %* þ ; 1·5
Lovejoy et al.
(2002)(65)
4 weeks
per arm
Study 1, n 20, healthy,
mean 25 (SD 1) years
Prospective cohort (no
control) habitual diet þ
almonds
100 g/d almonds Glucose NS NS-G; 0·2
Insulin NS NS-G; 0·1
Study 2, n 30, Dm, mean
54 (SD 2) years
RCT, cross-over, HF
(control) with/without
almonds and LF
(control) with/without
almonds
57–113 g/d (10 %
energy) almonds
HF glucose NS NS-G; 0·3
LF glucose NS NS-G; 0·2
HF insulin NS NS-G
LF insulin NS NS-G
HF HbA1c NS NS-G
LF HbA1c NS NS-G
Jenkins et al.
(2011)(66)
3 months n 117 (control ¼ 37,
37 g/d nut ¼ 40, 75 g/d
nut ¼ 40), Dm, M and
F, mean 62 (SD 10)
years
RCT, parallel, 75 g/d nut v.
37 g/d nut þ half-dose
muffin v. muffin (control)
75 or 37 g/d
mixed nuts§
Glucose (75 g) NS NS-G; 0·2
Glucose (37 g) NS NS-G; 0·2
HbA1c (75 g) NS NS-G; 0·0
HbA1c (37 g) NS NS-G; 0·0
Thomazella et al.
(2011)(48)
12 weeks n 40 (control ¼ 19, Med
diet ¼ 21), M, CVD,
mean 55 (SD 5) years
Prospective controlled
study, Med diet (includ-
ing nuts) v. LF diet
(control)
10 g/d any nuts Glucose NS NS-G; 0·4
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Table 3. Continued
Author Time Participants Study design Amount/type of nuts Outcomes†
Effect;
effect size
Mercanligil et al.
(2007)(74)
4 weeks
per arm
n 15, M, mean 48 (SD 8)
years, hypercholestero-
laemic
Two-period study, LF diet
(control) v. LF þ hazel-
nuts, non-isoenergetic
40 g/d hazelnuts
(12 % energy)
Glucose NS NS-G; 0·3
Llorente-Corte´s
et al. (2011)(67)
12 weeks n 49 (OO ¼ 16, nut ¼ 15,
control ¼ 15), high risk
of CVD, M and F, mean
66 (SD 7) years
RCT, parallel, Med diet þ
OO v. Med diet þ nuts
v. LF diet (control)
(PREDIMED)
30 g/d mixed nuts‡ Glucose NS NS-G; 0·4
Wien et al.
(2003)(76)
24 weeks n 52 (control ¼ 28, nut
¼ 24), M and F, over-
weight/obese, mean 55
(SD 2) years
RCT, parallel, iso-
energetic, LE diet þ
almond v. CHO (control)
84 g/d almonds Glucose NS NS-G; 0·0
Insulin NS NS-G; 0·3
HOMA NS NS-G; 0·0
HbA1c NS NS-G; 0·0
Zaveri & Drum-
mond (2009)(63)
12 weeks n 36 (control ¼ 13, cereal
bar ¼ 14, almond
¼ 18), healthy, M and F,
mean 40 (SD 7) years
RCT, parallel, healthy diet
with/without nuts or
cereal bar (control)
56 g/d almonds Glucose NS NS-G
Insulin NS NS-G
Li et al. (2010)(75) 12 weeks n 31, obese, M and F,
(control ¼ 28 pistachio
¼ 31), mean 45 (SD 7)
years
RCT, parallel, isoenergetic
prescribed diet þ
pretzels (control) or
pistachios
53 g/d pistachios Glucose NS NS-G; 20·6
Insulin NS NS-G; 1·8
Tapsell et al.
(2004)(69)
6 months n 41 (control ¼ 21,
walnut ¼ 20), Dm, M
and F, mean 60 (SD 8)
years
RCT, parallel, isoenergetic
LF diet (control)
with/without walnuts
30 g/d walnuts HbA1c NS NS-G; 0·0
Tapsell et al.
(2009)(70)
12 months n 34 (control ¼ 17,
walnut ¼ 17), over-
weight, Dm, M and F,
mean 55 (SD 9) years
RCT, parallel, isoenergetic
LF diet (control)
with/without walnuts
30 g/d walnuts Glucose NS NS-G; 0·4
Insulin " 6 %* NS-G; 20·3
HbA1c NS NS-G; 0·1
Mukuddem-Peter-
sen et al. (2007)(71)
8 weeks n 64 (control ¼ 22,
walnut ¼ 21, cashew
¼ 21), Met-S, M and F,
mean 45 (SD 8) years
RCT, parallel, isoenergetic
LF diet (control)
with/without walnuts or
cashews
63–108 g/d walnuts/
cashews
Cashew
glucose " 13 %*
NS-G; 20·8
Walnut glucose NS NS-G; 20·6
Ma et al. (2010)(72) 8 weeks
per arm
n 21, Dm, M and F, mean
58 (SD 8) years
RCT, cross-over,
ad libitum diet (control)
with/without nuts, not
isoenergetic, 8 weeks
washout
56 g/d walnuts Glucose NS NS-G; 20·3
Insulin Ns NS-G; 0·7
HOMA NS NS-G; 20·4
HbA1c NS NS-G; 0·0
Kasim-Karakas
et al. (2004)(73)
3 months n 17, mean 34 (SD 5)
years, F, PCOS
Prospective cohort, iso-
energetic habitual diet
(control) v. walnuts
106 g/d walnuts Glucose " 19 %* 2 ; 24·5
Insulin NS NS-G; 0·2
HOMA NS NS-G; 1·0
Glucose, fasting glucose; M, male; F, female; Dm, type 2 diabetes; Med diet, Mediterranean diet; # , reduction; RR, relative risk; þ , significant reduction; X-sect, cross-sectional; PREDIMED, PREvencion con DIeta MEDiterranea;
N/A, not available; NS-G, no significant change; MESA, Multi-Ethnic Study of Atherosclerosis; NHANES, National Health and Nutrition Survey; RCT, randomised controlled trial; OO, olive oil; LF, low-fat; Met-S, metabolic
syndrome; insulin, fasting insulin; HOMA, homeostatic model assessment of insulin resistance; NS, no significant difference; PCOS, polycystic ovary syndrome; HF, high-fat; LE, low-energy; CHO, carbohydrate; " , increase;
–, significant increase
* P#0·05.
† Outcome (active v. control) for intervention studies.
‡ Mixed nuts ¼ walnuts, almonds and hazelnuts.
§ Mixed nuts ¼ almonds, pistachios, walnuts, groundnuts, hazelnuts, pecans, cashews and macadamias.
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Table 4. Studies measuring effect of nut consumption on blood pressure (BP)
Author Time Subjects Study design Amount/type of nuts Outcomes†
Effect;
effect size
Prospective cohort studies measuring the effect of nut consumption on HT (studies are presented in order of efficacy)
Steffen et al.
(2005)(78)
15 years n 4304, M and F,
healthy, 18–30 years
Prospective cohort
(CARDIA), diet history
and prevalence of HT
Any nuts HR Inverse relationship
between nut consump-
tion and HT
þ
, 0·1 serves/d 1·0
0·1–0·3 serves/d 0·84 (95 % CI 0·73, 0·98) P for trend ¼0·04
. 0·3 serves/d 0·85 (95 % CI 0·72, 0·99)
Djousse´ et al.
(2010)(77)
12 months n 15966, free of HT, M
and F, mean 52
(range 45–64) years
Prospective cohort, FFQ
and self-reported risk
of HT (Physicians’
Health Study)
Any nuts HR Nut consumption associ-
ated with # risk of
hypertension (P¼0·01)
þ
None 1·0
1–3 serves/month 0·93 (95 % CI 0·86, 1·01)
1 serves/week 0·94 (95 % CI 0·86, 1·03)
2–6 serves/week 0·87 (95 % CI 0·79, 0·96)
$ 7 serves/week 0·77 (95 % CI 0·64, 0·93)
Weng et al.
(2013)(79)
9 years n 9913, healthy, M and
F, mean 53 (SD 6)
years
Prospective cohort,
ARIC, FFQ and BP
Quintiles of nut
consumption
HR Nut intake inversely
related to incidence of
HT (P¼0·02)
þ
1·2 (95 % CI 0·98, 1·27)
0·96 (95 % CI 0·87, 1·07)
0·91 (95 % CI 0·81, 1·03)
0·87 (95 % CI 0·77, 0·97)
Martı´nez-Lapiscina
et al. (2010)(80)
4 years n 17177, healthy, M and
F, mean 36 (range
25–51) years
Prospective cohort
(SUN) study, FFQ and
self-reported HT
Any nuts, never/rarely to
2 þ /week
HR highest v. lowest
intake
No association with HT
and nut consumption
NS-BP
Cross-sectional studies measuring effect of nut consumption on BP/HT (studies are presented in order of efficacy)
O’Neil et al.
(2011)(49)
X-sect n 13292, general
population, M and F,
19–50 þ years
(20 % nut consumers)
1999–2004 NHANES,
24 h recall and BP
HT v. non-consumers BP v. non-consumers
(A) SBP # 1 mmHg
(P,0·01)
þ
‘All’ nut group $ 7 g/d
(A)
# 3 %* (A) DBP NS NS-BP
Tree nut group $ 7 g/d
(B)
# 3 %* (B) SBP # 1 mmHg
(P,0·01)
þ
(B) DBP NS NS-BP
Nettleton et al.
(2008)(52)
X-sect n 5089, healthy, M and
F, 45–84 years
MESA, FFQ and BP Quintiles of healthy diet-
ary pattern (including
any nuts)
No data provided No association of SBP or
DBP with healthy diet-
ary pattern
NS-BP
Alvarez Leo´n et al.
(2006)(50)
X-sect n 578, healthy or Met-S,
M and F, 18–75 years
ENCA, FFQ and BP Tertiles (any nuts) OR HT No association of BP
with nut consumption
NS-BP
Nuts T1 1·0
Nuts T2 0·73 (95 % CI 0·41, 1·28)
Nuts T3 0·83 (95 % CI 0·47, 1·46)
Ibarrola-Jurado
et al. (2013)(81)
X-sect n 7210, high risk of CVD,
M and F, mean 68
(SD 6) years
X-sect, FFQ and
prevalence of HT
(PREDIMED)
Tertiles (any nuts)
T1 , 28 g/week
T2 28–84 g/week
T3 . 84 g/week
OR HT No association of HT
with nut consumption
NS-BP
1·0
0·96 (95 % CI 0·71, 1·29)
1·12 (95 % CI 0·81, 1·53)
Chronic effects of nuts on resting BP (studies are presented in order of efficacy)
Wien et al.
(2003)(76)
24 weeks n 52 (control ¼ 28 nut
¼ 24), M and F, over-
weight/obese, mean
55 (SD 2) years
RCT, parallel, iso-
energetic, LE diet þ
almond v. CHO
(control)
84 g/d almonds SBP # 14 mmHg* þ ; 0·7
DBP NS NS-BP; 0·0
Estruch et al.
(2006)(58)
12 weeks n 772 (control ¼ 257,
OO ¼ 257, nut
¼ 258), high risk of
CVD, M and F, mean
69 (SD 6) years
RCT, parallel, Med diet
þ OO v. Med diet þ
nuts v. LF diet
(control) (PREDIMED)
30 g/d mixed nuts‡ SBP # 7 mmHg* þ ; 0·3
DBP # 3 mmHg* þ ; 0·2
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Table 4. Continued
Author Time Subjects Study design Amount/type of nuts Outcomes†
Effect;
effect size
Esposito et al.
(2004)(47)
2 years n 180 (control ¼ 90,
Med diet ¼ 90),
Met-S, M and F,
mean 44 (SD 6) years
RCT, parallel, Med diet
(including nuts)
v. prudent diet
(control)
20–50 g/d walnuts SBP # 3 mmHg* þ ; 0·7
DBP # 2 mmHg* þ ; 0·7
Adamsson et al.
(2011)(46)
4 weeks n 86 (control ¼ 42,
NORDIET ¼ 44), M
and F, hypercholes-
terolaemic, mean 53
(SD 8) years
RCT, parallel, NORDIET
(high fibre, fish, LF
dairy, nuts) v. habitual
diet (control)
Ad libitum almonds SBP # 6 mmHg* þ ; 0·6
DBP # 3 mmHg* þ ; 0·4
Llorente-Corte´s
et al. (2011)(67)
12 weeks n 49 (OO ¼ 16, nut
¼ 15, control ¼ 15),
high risk of CVD, M
and F, mean 66 (SD 7)
years
RCT, parallel, Med diet
þ OO v. Med diet þ
nuts v. LF diet
(control) (PREDIMED)
30 g/d mixed nuts‡ SBP # 7 mmHg* þ ; 0·4
DBP NS NS-BP; 0·2
Fito et al.
(2007)(85)
12 weeks n 372 (OO ¼ 123, nut
¼ 128, control ¼ 127),
high risk of CVD, M
and F, mean 66 (SD 9)
years
RCT, parallel, Med diet
þ OO v. Med diet þ
nuts v. LF diet
(control) (PREDIMED)
30 g/d mixed nuts‡ SBP # * (data N/A) þ
DBP # * (data N/A) þ
Jenkins et al.
(2008)(82)
1 year n 50, hyperlipidaemic, M
and F, mean 59 (SD 1)
years
Single-phase prospective
study, pre-/post-
measures, sterol þ
soya þ almonds
(no control)
23 g/4·2 MJ per d
almonds
(v.. baseline)
SBP # 4 mmHg* þ ; 0·4
DBP # 2 mmHg* þ ; 0·5
Mena et al.
(2009)(84)
12 weeks n 106 (control ¼ 36, nut
¼ 35, OO ¼ 35), Dm,
risk of CVD, M and F,
mean 66 (SD 7) years
RCT, parallel, Med diet
þ OO v. Med diet þ
nuts v. LF diet
(control) (PREDIMED)
30 g/d mixed nuts‡ (v. baseline)
SBP # 3 mmHg* þ
DBP # 2 mmHg* þ
Toledo et al.
(2013)(83)
4 years n 7158 (control ¼ 2064,
OO ¼ 2345, nuts
¼ 2065), M and F, risk
of CVD, mean 67
(SD 6) years
RCT, parallel, Med diet
þ OO v. Med diet þ
nuts v. LF diet
(control) (PREDIMED)
30 g/d mixed nuts‡ SBP NS NS-BP; 0·2
DBP # 2 mmHg* þ ; 1·1
Wien et al.
(2010)(61)
16 weeks n 65 (control ¼ 32, nut
¼ 33), prediabetes,
M and F, mean 53
(SD 9) years
RCT, parallel, American
Diabetes Association
diet (control) with/
without almonds
56 g/d almonds SBP NS NS-BP; 0·2
DBP NS NS-BP; 0·2
Jenkins et al.
(2011)(66)
3 months n 117 (control ¼ 37,
37 g/d nut ¼ 40,
75 g/d nuts ¼ 40),
Dm, M and F, mean
62 (SD 10) years
RCT, parallel, 75 g/d nut
v. 37 g/d nuts þ
half-dose muffin
v. muffin (control)
75 or 37 g/d mixed nuts§ SBP NS NS-BP; 0·2
DBP NS NS-BP; 0·2
Spaccarotella et al.
(2008)(146)
8 weeks per
arm
n 21, healthy, M and F,
mean 66 (range
45–75) years
RCT, cross-over, habit-
ual diet (control) with/
without walnuts
(2 weeks washout)
75 g/d walnuts SBP NS NS-BP; 0·1
DBP NS NS-BP; 0·2
Wu et al. (2010)(68) 12 weeks n 277 (control ¼ 95,
flax ¼ 94, nut ¼ 94),
Met-S, M and F, mean
49 (SD 8) years
RCT, parallel,
isoenergetic LF diet
(control) with/without
flaxseeds or walnuts
30 g/d walnut flour SBP NS NS-BP; 0·1
DBP NS NS-BP; 0·0
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Table 4. Continued
Author Time Subjects Study design Amount/type of nuts Outcomes†
Effect;
effect size
Sari et al.
(2010)(59)
4 weeks per
arm
n 32, healthy, M, mean
22 (range 21–24)
years
Prospective cohort,
isoenergetic Med diet
(control) with/without
pistachios, no washout
80–100 g/d pistachios SBP NS NS-BP; 0·3
DBP NS NS-BP; 0·1
Din et al.
(2011)(109)
4 weeks per
arm
n 30, healthy, M and F,
mean 23 (SD 3) years
RCT, cross-over,
non-isoenergetic
habitual diet (control)
with/without walnuts,
no washout
15 g/d walnuts SBP NS NS-BP; 0·3
DBP NS NS-BP; 20·1
Thomazella et al.
(2011)(48)
12 weeks n 40 (control ¼ 19, Med
diet ¼ 21), M, CVD,
mean 55 (SD 5) years
Prospective controlled
study, Med diet
(including nuts)
v. LF diet (control)
10 g/d any nuts SBP NS NS-BP; 0·2
DBP NS NS-BP; 0·1
Mukuddem-Peter-
sen et al. (2007)(71)
8 weeks n 64 (control ¼ 22, nut
¼ 21, cashew ¼ 21),
Met-S, M and F, mean
45 (SD 8) years
RCT, parallel, iso-
energetic LF diet
(control) with/without
walnuts (W) or
cashews (C)
63–108 g/d walnuts/ca-
shews
SBP NS W and C NS-BP; 0·1
DBP NS W and C NS-BP; 0·1
Iwamoto et al.
(2002)(147)
4 weeks per
arm
n 80, healthy, M and F,
mean 24 (SD 9) years
RCT, cross-over,
Japanese diet with/
without walnuts
(no washout)
44–58 g/d walnuts SBP NS NS-BP
DBP NS NS-BP
West et al.
(2012)(107)
4 weeks per
arm
n 25, hypercholestero-
laemic, M and F,
mean 48 (SD 2) years
RCT, cross-over, LF diet
(control) v. low-dose
pistachios v. high-dose
pistachios, no washout
32–63 g/d (A) or 63–
126 g/d (B) pistachios
(A) SBP NS NS-BP; 0·1
(A) DBP NS NS-BP; 0·1
(B) SBP NS NS-BP; 0·0
(B) DBP NS NS-BP; 0·0
Jenkins et al.
(2003)(89)
4 weeks n 25 (control ¼ 12, nut
¼ 13), hyperlipidae-
mic, M and F, mean
59 (SD 1) years
RCT, parallel, plant
sterol þ soya þ
almond v. statin
v. LF diet (control)
14 g/4·2 MJ almonds SBP NS NS-BP; 0·1
DBP NS NS-BP; 0·1
Jenkins et al.
(2002)(99)
1 month per
arm
n 27, hyperlipidaemic, M
and F, mean 64 (SD 9)
years
RCT, cross-over,
isoenergetic almonds
v. half-dose almonds
þ half-dose muffin
v. muffin (control)
36 or 73 g/d almonds SBP NS NS-BP; 0.0
DBP NS NS-BP; 0·0
Hiraoka-Yamamoto
et al. (2004)(148)
3 weeks n 71 (control ¼ 24,
coconut ¼ 23, nut
¼ 24), F, students,
mean 19 (SD 3) years
RCT, parallel, coconut
v. macadamia v. butter
(control)
10 g/d macadamias SBP NS NS-BP; 0·0
Damesceno et al.
(2011)(149)
4 weeks per
arm
n 18, hypercholestero-
laemic, M and F,
mean 56 (SD 13) years
RCT, cross-over,
isoenergetic Med diet
þ OO (control) v. Med
diet þ walnuts v. Med
diet þ almonds, no
washout
40–65 g/d walnuts SBP NS NS-BP; 0·2
DBP NS NS-BP; 0·2
50–75 g/d almonds SBP NS NS-BP; 0·1
DBP NS NS-BP; 0·2
Olmedilla-Alonso
et al. (2008)(150)
5 weeks per
arm
n 25, high risk of CVD,
M and F, mean 54
(SD 8) years
RCT, cross-over, meat
product with/without
20 % walnut flour,
1-month washout
19 g/d walnuts SBP NS NS-BP; 20·2
DBP NS NS-BP; 0·0
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Table 4. Continued
Author Time Subjects Study design Amount/type of nuts Outcomes†
Effect;
effect size
Casas-Agustench
et al. (2011)(60)
12 weeks n 50 (control ¼ 25 nut
¼ 25), Met-S, M and
F, mean 52 (SD 8)
years
RCT, parallel,
isoenergetic healthy
diet with/without nuts
30 g/d mixed nuts‡ SBP NS NS-BP; 20·2
DBP NS NS-BP; 20·1
Nouran et al.
(2010)(151)
4 weeks n 108 (control ¼ 54,
groundnut ¼ 54),
hypercholesterolae-
mic, M and F, mean
43 (SD 10) years
RCT, parallel, habitual
diet (control) with/
without groundnuts
77 g/d groundnuts SBP NS NS-BP; 0·0
DBP NS NS-BP; 0·0
Ros et al.
(2004)(98)
4 weeks per
arm
n 20, hypercholestero-
laemic, M and F,
mean 55 (range
26–75) years
RCT, cross-over,
isoenergetic Med diet
(control) with/without
walnuts, no washout
40–65 g/d walnuts SBP NS NS-BP; 0·0
DBP NS NS-BP; 0·1
Lo´pez-Uriarte et al.
(2010)(106)
12 weeks n 50 (control ¼ 25, nut
¼ 25), Met-S, M and
F, mean 52 (SD 8)
years
RCT, parallel, American
Heart Association diet
(control) with/without
nuts, not isoenergetic
30 g/d mixed nuts‡ SBP NS NS-BP
DBP NS NS-BP
Sola` et al.
(2012)(86)
4 weeks per
arm
n 113 (control ¼ 28, nut
¼ 28, nut þsterol
¼ 30, nut þ sterol þ
fibre ¼ 27), risk of
CVD, M and F, mean
54 (SD 9) years
RCT, parallel, iso-
energetic cocoa þ nut
v. cocoa þ nut þ
sterol v. cocoa þ nut
þ sterol þ fibre
v. cocoa (control)
30 g/d hazelnuts SBP NS NS-BP
DBP NS NS-BP
Sabate et al.
(1993)(152)
4 weeks per
arm
n 18, healthy, M, mean
30 (range 21–43)
years
RCT, cross-over,
isoenergetic LF diet
(control) with/without
walnuts, no washout
20 % energy walnuts
(84 g/4·4 MJ per d)
SBP NS NS-BP
DBP NS NS-BP
Edwards et al.
(1999)(153)
3 weeks per
arm
n 10, hypercholestero-
laemic, M and F,
mean 46 (range
41–64) years
RCT, cross-over, iso-
energetic habitual diet
(control) with/without
pistachios
(20 % energy)
(20 % energy) pistachios SBP NS NS-BP
DBP NS NS-BP
Spiller et al.
(2003)(154)
4 weeks n 38 (raw ¼ 14, roasted
¼ 14 butter ¼ 10), M
and F, 32–74 years,
hypercholesterolaemic
RCT, parallel, LF diet þ
nuts (roasted
v. roasted butter
v. raw (control))
100 g/d almonds/almond
butter
SBP NS NS-BP
DBP NS NS-BP
Jenkins et al.
(2002)(88)
4 weeks per
arm
n 13, hyperlipidaemic, M
and F, mean 65 (SD 3)
years
Prospective cohort,
LF diet followed by
portfolio diet (soya/
plant sterol/fibre/nuts)
28 g/8·4 MJ per d
almonds
SBP NS NS-BP
DBP NS NS-BP
Schutte et al.
(2006)(155)
8 weeks n 62 (control ¼ 21,
walnut ¼ 20, cashew
¼ 21) Met-S, M and F,
45 years
RCT, parallel,
isoenergetic LF diet
(control) with/without
walnuts or cashews
63–103 g/d walnuts or
cashews (20 %
energy)
SBP NS NS-BP
DBP NS NS-BP
Sheridan et al.
(2007)(156)
4 weeks per
arm
n 15, hypercholestero-
laemic, M and F,
mean 60 (SD 12) years
RCT, cross-over,
isoenergetic habitual
diet (control) with/
without pistachios,
no washout
56–84 g/d pistachios
(15 % energy)
SBP NS NS-BP; 0·1
DBP NS NS-BP; 0·1
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fasting glucose or insulin(48,63–76). One study that failed to
achieve an improvement in insulin sensitivity sup-
plemented participants’ diets with 100 g almonds/d for 4
weeks. In this study there was a significant weight gain,
which may have masked any benefit on insulin control(65).
Unexpected increases in plasma glucose (but not insulin)
were observed with walnut and cashew consumption in
women with polycystic ovary syndrome and adults with
the metabolic syndrome, respectively(71,73). Other studies
investigated HbA1c in individuals with type 2 diabetes
and found that 28 g walnuts/d and 36 g almonds/d reduced
HbA1c by 4 %(62,64). However, in other individuals, HbA1c
did not change with 37–75 g mixed nuts/d(66), 30–50 g
walnuts/d(69,70,72) or 57–112 g almonds/d (for 4 weeks)(65).
The lack of effect in the latter study may have been due to
the short intervention time. Whilst epidemiological studies
suggest an association of nut consumption with improve-
ment in glucoregulation and diabetes risk, not all evidence
from randomised controlled trials is supportive. Some
inconsistencies in findings may be attributed to variations
in the number or health status of the study participants,
length of trial, or the dose of nuts used.
Weighted mean changes in glucoregulation indicate sig-
nificant reductions in fasting insulin and HOMA scores of
14 (95 % CI 224, 24·5) % and 34 (95 % CI 249, 219) %,
respectively, with small non-significant reductions of 2·8
(95 % CI 26·9, 1·3) % and 1 (95 % CI 23, 0·9) % for fasting
glucose and HbA1c, respectively. This indicates positive
effects of nut consumption on the most widely accepted
markers of glucoregulation. Overall, there is considerable
evidence of benefits of nut consumption for glycaemic
control and insulin sensitivity observed after 4–6 weeks
of consumption. However, inconsistencies make it difficult
to reach precise conclusions on the role of nuts. The target
population, dose and length of consumption (particularly
to observe changes in HbA1c) need to be further con-
sidered so that targeted advice can be provided to
consumers.
Effects of nut consumption on blood pressure
Studies measuring the effect of nut consumption on blood
pressure are found in Table 4. Nuts consumed included
walnuts, pistachios, groundnuts, almonds, cashews, hazel-
nuts, macadamias and mixed nuts in different forms includ-
ing oil, whole nuts and nut flour added to baked goods. As
with many studies using whole-food products, participant
blinding was not possible. Amounts consumed ranged
from 10 to 108 g/d ( 13 ounce to 4 ounces/d) (approximately
2–20 % of energy intake). The length of consumption
ranged from 3 weeks to 2 years. Whilst there were thirty-
six intervention trials that reported on the effect of chronic
consumption of nuts on blood pressure, most measured
blood pressure as a secondary outcome. Comparisons
were made with a healthy diet (sixteen studies), habitual
diet (seven studies) or other food products includingTa
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Table 5. Effects of nut consumption on inflammatory markers
Author Time Subjects Study design Amount/type nuts Measure Outcome†
Effect;
effect size
Cross-sectional studies measuring effects of nut consumption on inflammatory markers (studies are presented in order of efficacy)
Jiang et al.
(2006)(90)
X-sect n 6080, healthy, M and F,
mean 62 (range 45–84)
years
X-sect, FFQ and inflamma-
tory markers, MESA
Rare to . 4 serves/week
any nuts and seeds
CRP Negative correlation** þ
r 0·06
IL-6 Negative correlation** þ
r 0·05
Salas-Salvado´
et al.
(2008)(91)
X-sect n 772, high risk of CVD, M
and F, mean 68
(range 55–80) years
X-sect, FFQ and inflamma-
tory markers (PREDIMED
trial)
Tertiles (any nuts)
T1 , 3·92 g
ICAM # 17 %* þ
VCAM NS NS-I
T2 3·92–10·84 g IL-6 NS NS-I
T3 . 10·84 g CRP NS NS-I
O’Neil et al.
(2011)(49)
X-sect n 13292, general population,
M and F, mean 57 years
1999–2004 NHANES, 24 h
recall and CRP
All nuts # 7 g/d CRP NS NS-I
Tree nuts 7 g/d CRP # 12 %* þ
Li et al.
(2009)(92)
X-sect n 6309, F, Dm FFQ and inflammatory
markers
0– . 5 serves/week; 1
serve ¼ 28 g any nuts
ICAM NS NS-I
E-selectin NS NS-I
Chronic effects of nuts on inflammatory markers (studies are presented in order of efficacy)
Zhao et al.
(2004)(93)
6 weeks
per arm
n 23, hypercholesterolaemic,
M and F, mean 50 (SD 2)
years
RCT, cross-over, LA diet
(walnut þ walnut oil) v.
ALA diet (flax þ walnut þ
walnut oil) v. American
diet (control), no washout,
isoenergetic
37 g/d walnuts þ15 g/d
walnut oil
CRP (ALA) # 75 %* þ
VCAM (ALA) # 12 %* þ
E-selectin (ALA) # 12 %* þ
E-selectin (LA) # 7 % þ
CRP (LA) # 35 % þ
VCAM (LA) # 7 % þ
Mena et al.
(2009)(84)
3 months n 106 (control ¼ 36, OO
¼ 45, nuts ¼ 35), high
risk of CVD, M and F,
mean 68 (SD 8) years
RCT, parallel, Med diet þ
OO v. Med diet þ nuts v.
LF diet (control)
(PREDIMED)
30 g/d mixed nuts‡ IL-6 # 40 %* þ ; 0·3
ICAM # 52 %* þ ; 1·1
VCAM # 33 %* þ ; 1·5
CRP # 78 %* þ ; 0·4
E-selectin NS NS-I; 20·2
P-selectin NS NS-I; 0·2
Esposito et al.
(2004)(47)
2 years n 180 (control ¼ 90, Med
diet ¼ 90), Met-S, M and
F, mean 44 (SD 6) years
RCT, parallel, Med diet
(including walnuts) v.
prudent diet (control)
20–50 g/d walnuts CRP # 36 %* þ
IL-6 # 28 %* þ
IL-7 # 21 %* þ
IL-18 # 9 %* þ
Sola` et al.
(2012)(86)
4 weeks
per arm
n 113 (control ¼ 28, nut
¼ 28, nut þ sterol ¼ 30,
nut þ sterol þ fibre
¼ 27), risk of CVD, M and
F, mean 54 (SD 9) years
RCT, parallel, isoenergetic
cocoa þ hazelnut (A) v.
cocoa þ hazelnut þ
phytosterol (B) v. cocoa þ
hazelnut þ phytosterol þ
soluble fibre (C) v. cocoa
(control), no washout
30 g/d hazelnuts VCAM (A) (B) NS NS-I; 0·1
VCAM (C) NS NS-I; 0·0
ICAM (A) (B) (C) NS NS-I; 0·0
IL-6 (A) (B) (C) NS NS-I
CRP (A) (B) NS NS-I
CRP (C) # 33 %* NS-I
Sari et al.
(2010)(59)
4 weeks
per arm
n 32, healthy, M, mean 22
(range 21–24) years
Prospective cohort, iso-
energetic Med diet
(control) with/without
pistachios, no washout
80–100 g/d pistachios IL-6 # 25 %* þ ; 0·4
CRP NS NS-I
TNFa NS NS-I; 0·0
Jenkins et al.
(2002)(99)
4 weeks
per arm
n 13, M and F, mean 65
(SD 3) years, hyper-
lipidaemic
Prospective cohort, LF diet
(control) and portfolio diet
(soya/sterol/fibre/nuts)
28 g/d almonds CRP # 26 % þ
Jenkins et al.
(2003)(89)
4 weeks n 46 (control ¼ 16, statin
¼ 14, nut ¼ 16), hyper-
lipidaemic, M and F, mean
59 (SD 1) years
RCT, parallel, isoenergetic
statin v. sterol þ soya þ
almonds v. LF diet
(control)
14 g/4·2 MJ almonds per d CRP # 18 %* þ ; 0·1
Canales et al.
(2011)(97)
5 weeks
per arm
n 22, risk of CVD, M and F,
mean 55 (SD 2) years
RCT, cross-over, meat pro-
duct (control) with/without
walnuts, 5 weeks washout
21 g/d walnuts VCAM # 12 %* þ ; 0·4
ICAM # 17 %* þ ; 0·3
Jenkins et al.
(2005)(94)
1 month
per arm
n 34, hyperlipidaemic, M and
F, mean 55 years (SD 7)
years
RCT, cross-over, iso-
energetic statin v. phyto-
sterol þ soya þ almonds
v. LF diet (control), 4
weeks washout
14 g/4·2 MJ almonds CRP (all subjects) NS NS-I; 0·0
CRP (subjects # 3·5 mg/l) # 9 %* þ ; 0·4
J.
A
.
B
arb
o
u
r
et
a
l.
1
4
4
Nutrition Research Reviews
https:/w
w
w
.cam
bridge.org/core/term
s. https://doi.org/10.1017/S0954422414000079
D
ow
nloaded from
 https:/w
w
w
.cam
bridge.org/core. U
niversity of Southern Q
ueensland, on 05 Jun 2017 at 00:00:53, subject to the C
am
bridge C
ore term
s of use, available at
Table 5. Continued
Author Time Subjects Study design Amount/type nuts Measure Outcome†
Effect;
effect size
Rajaram et al.
(2010)(95)
4 weeks
per arm
n 25, healthy, M and F,
mean 41 (SD 13) years
RCT, cross-over, low-almond
diet (L) v. high-almond
diet (H) v. healthy heart
diet (control), no washout
Low almond (L) (34 g/8·4 MJ
per d)
High almond (H)
(68 g/8·4 MJ per d)
E-selectin (H) # 8 %* þ ; 0·5
E-selectin (L) NS NS-I; 0·0
CRP (H) # 5 %* þ ; 0·1
CRP (L) # 9 %* þ ; 0·1
IL-6 (H) (L) NS NS-I; 0·1
Ros et al.
(2004)(98)
4 weeks
per arm
n 20, M and F, hypercholes-
terolaemic, mean 55
(range 26–75) years
RCT, cross-over,
isoenergetic Med diet
(control) with/without nuts,
no washout
About 65 g/d walnuts
(32 % energy)
VCAM # 12 %* þ ; 0·5
ICAM NS NS-I; 0·3
CRP NS NS-I; 0·0
Estruch et al.
(2006)(58)
3 months n 772 (control ¼ 257, OO
¼ 257, nut ¼ 258), high
risk of CVD, M and F,
mean 69 (SD 6) years
RCT, parallel, Med diet þ
OO v. Med diet þ nuts
v. LF diet (control)
(PREDIMED)
30 g/d mixed nuts‡ CRP NS NS-I
ICAM Data N/A* þ
VCAM Data N/A* þ
IL-6 Data N/A* þ
Chiang et al.
(2012)(96)
4 weeks
per arm
n 25, hyperlipidaemic, M and
F, mean 33 (range
23–65) years
RCT, cross-over,
isoenergetic fatty fish v.
walnuts v. no nut/fish
(control)
43 g/10 MJ walnuts per d CRP NS NS-I
ICAM NS NS-I
TNF-a NS NS-I
IL-1b and IL-6 NS NS-I
E-selectin NS v. control NS-I
( # v. fish*) þ
Kasim-Kara-
kas et al.
(2004)(73)
3 months n 17, mean 34 (SD 5) years,
F, PCOS
Prospective cohorts
isoenergetic habitual diet
(control) v. walnuts
106 g/d walnuts TNF-a NS NS-I; 1·0
Jenkins et al.
(2011)(66)
3 months n 117 (control ¼ 37,
37 g/d ¼ 40, 75 g/d ¼ 40),
Dm, M and F, mean 62
(SD 10) years
RCT, parallel, 75 g/d nuts v.
37 g/d nuts þ half muffin
v. muffin (control)
75 or 37 g/d mixed nuts§ CRP (full dose) NS NS-I; 0·1
CRP (half dose) NS NS-I; 0·2
Jenkins et al.
(2002)(99)
1 month
per arm
n 27, hyperlipidaemic, M and
F, mean 64 (SD 9) years
RCT, cross-over almonds v.
half almonds þ half muffin
v. muffin (control)
73 g/d almonds or 36 g/d
almonds
CRP NS NS-I; 0·0
Adamsson
et al.
(2011)(46)
4 weeks n 86 (control ¼ 42, NOR-
DIET ¼ 44), hypercholes-
terolaemic, M and F,
mean 53 (SD 8) years
RCT, parallel, NORDIET
(fibre, fish, LF dairy, nuts)
v. habitual diet (control)
Almonds ad libitum CRP NS NS-I; 0·1
Thomazella
et al.
(2011)(48)
3 months n 40 (control ¼ 19, Med
diet ¼ 21), M, CVD,
mean 55 (SD 5) years
Prospective controlled study,
Med diet (including nuts)
v. LF diet (control)
10 g/d any nuts CRP NS NS-I; 0·3
ICAM NS NS-I; 0·3
VCAM NS NS-I; 0·0
Lo´pez-Uriarte
et al.
(2010)(106)
12 weeks n 50 (control ¼ 25, nut
¼ 25), Met-S, M and F,
mean 5 (SD 8) years
RCT, parallel, American
Heart Association diet
(control) with/without nuts,
not isoenergetic
30 g/d mixed nuts‡ ICAM NS NS-I; 0·3
VCAM NS NS-I; 0·6
Damasceno
et al.
(2011)(149)
4 weeks
per arm
n 18, M and F, mean 56
(SD 13) years, hyper-
cholesterolaemic
RCT, cross-over, iso-
energetic Med diet þ
walnuts (W) v. almonds
(A) v. OO (control), no
washout
40–65 g/d walnuts (W),
50–75 g/d almonds (A)
VCAM (W and A) NS NS-I; 20·2
ICAM (W and A) NS NS-I; 0·2
CRP (W and A) NS NS-I; 0·2
Kalgaonkar
et al.
(2011)(62)
6 weeks n 31 (almond ¼ 14, walnut
¼ 17), F, PCOS, age
range 20–45 years
Pre-/post-measures, walnuts
v. almonds
36 g/d walnuts (W), 26 g/d
almonds (A)
IL-6 (W v. A) NS NS-I; 1·3
TNF-a (W v. A) NS NS-I; 1·2
IL-1b (W v. A) NS NS-I; 0·9
CRP (W v. A) NS NS-I; 0·4
Kurlandsky &
Stot
(2006)(157)
6 weeks n 41 (control ¼ 10, choco-
late ¼ 10, nut ¼ 10, nut
þ chocolate ¼ 11),
healthy, F, mean 47
(SD 9) years
RCT, parallel, LF diet
(control) v. chocolate v.
almond (A) v. chocolate þ
almonds (CA)
60 g/d almonds CRP (CA) NS NS-I; 0·0
ICAM (CA) NS NS-I; 0·2
VCAM (CA) NS NS-I; 0·2
CRP (A) NS NS-I; 0·2
VCAM (A) NS NS-I; 0·1
ICAM (A) NS NS-I; 0·2
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butter, muffins, processed meat, olive oil and cocoa.
Of the studies, four compared habitual or healthy diets
with intervention diets including nuts (NORDIET(46) or a
Mediterranean diet(47,48)); only one of the studies reported
controlling for salt intake(46). The remaining studies used
control diets with unsalted nuts added as the intervention
but overall dietary salt intake was not specified. Four
prospective cohort studies measured blood pressure or
incidence of hypertension in participants consuming nuts.
The Physicians’ Study demonstrated a significant reduction
in self-reported hypertension after 12 months in those con-
suming nuts $ twice per week (hazard ratio 0·87; 95 % CI
0·79, 0·96) and greatest reduction with consumption $ 7
times per week (hazard ratio 0·77; 95 % CI 0·64, 0·93)(77).
However, salt intake and changes in weight were not
accounted for, which could have affected outcomes
observed. The Coronary Artery Risk Development in
Young Adults (CARDIA) Study demonstrated an inverse
relationship between nut consumption and prevalence of
hypertension despite those classified as the highest consu-
mers only consuming nuts $ 2 times per week (hazard
ratio 0·85; 95 % CI 0·64, 0·93)(78). In support of this, the
Atherosclerosis Risk in Communities (ARIC) Study also
reported that nut consumption was inversely related to a
reduced risk of hypertension; those who consumed
approximately two serves of nuts per week were at a
lower risk of hypertension than those who rarely or
never consumed nuts (hazard ratio 0·87; 95 % CI 0·77,
0·97)(79). In contrast, the SUN Study demonstrated no
association between hypertension and nut consumption
after a 4-year follow-up(80). However, the young educated
adult sample in this study is less likely to demonstrate
improvements in blood pressure with a dietary interven-
tion than older individuals who are more likely to have
higher blood pressure.
In all, four cross-sectional studies were identified com-
paring blood pressure or prevalence of hypertension in
nut consumers with low-/non-nut consumers. The National
Health and Nutrition Survey (NHANES) observed a general
population and found a 3 % lower risk of hypertension and
1 mmHg reduction in systolic and diastolic blood pressure
in nut consumers(49). The Canary Nutrition Survey demon-
strated a trend for reduced prevalence of hypertension
with higher nut consumption but this did not reach signifi-
cance(50). The Multi-Ethnic Study of Atherosclerosis (MESA)
in Spain did not find an association with a healthy dietary
pattern (incorporating an undetermined quantity of nuts)
and blood pressure(52). The authors suggest that routinely
assessed blood pressure may have increased risk factor
awareness, thereby attenuating associations with dietary
intake. No association was found with hypertension and
nut consumption in participants with a high risk of
CVD(81). However, 90 % of the participants were hyperten-
sive which may have made it difficult to demonstrate a
relationship in this population. It is more difficult to
account for health benefits from an individual food withTa
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Table 6. Chronic effect of nut consumption on endothelial vasodilator function (studies are presented in order of efficacy)†
Author Time Subjects Study design Amount/type nuts
Outcome
(active
v. control)
Effect;
effect size
Ros et al.
(2004)(98)
4 weeks
per arm
n 20, hypercholesterolaemic, M
and F, mean 55 (range
26–75) years
RCT, cross-over, isoenergetic Med diet
(control) with/without walnuts, no wash-
out
About 65 g/d walnuts (32 % energy) " 64 %* þ ; 0·3
Ma et al.
(2010)(72)
8 weeks
per arm
n 21, Dm, M and F, mean 58
(SD 8) years
RCT, cross-over, ad libitum diet (control)
with/without walnuts, 8 weeks washout
56 g/d walnuts " 45 %* þ ; 0·6
West et al.
(2010)(104)
6 weeks
per arm
n 20, hypercholesterolaemic, M
and F, mean 49 (SD 6) years
RCT, cross-over, American diet (control) v.
LA diet (flax þ walnut þ walnut oil) v.
ALA diet (walnut þ walnut oil),
no washout
37 g/d walnuts þ15 g/d walnut oil ALA " 34 %* þ ; 0·4
LA NS NS-EF; 0·1
Sari et al.
(2010)(59)
4 weeks
per arm
n 32, healthy, M, mean 22
(range 21–24) years
RCT, cross-over, isoenergetic Med diet
(control) with/without pistachios, no
washout
80–100 g/d pistachios (20 % energy) " 24 %* þ ; 1·0
Esposito et al.
(2010)(47)
2 years n 180 (control ¼ 90, Med diet
¼ 90), Met-S, M and F, mean
44 (SD 6) years
RCT, parallel, Med diet (including walnuts)
v. prudent diet (control)
20–50 g/d walnuts " 21 %* þ ; 0·9
Mercanligil et al.
(2007)(74)
4-week
period
n 15, M, mean 48 (SD 8) years,
hypercholesterolaemic
Two-period study, LF diet (control) v. LF þ
hazelnuts, non-isoenergetic
40 g/d hazelnuts (12 % energy) NS NS-EF
Lo´pez-Uriarte
et al.
(2010)(106)
12 weeks
per arm
n 50 (control ¼ 25, nut ¼ 25),
Met-S, M and F, mean 52
(SD 8) years
RCT, parallel, American Heart Association
diet (control) (mixed nuts, not iso-
energetic)
30 g/d mixed nuts‡ NS NS-EF; 0·0
Thomazella et al.
(2011)(48)
3 months n 40 (control ¼ 19, Med diet
¼ 21), M, CVD, mean 55
(SD 5) years
Prospective controlled study, Med diet
(including nuts) v. LF diet (control)
10 g/d any nuts NS NS-EF; 0·0
West et al.
(2012)(107)
4 weeks
per arm
n 25, hypercholesterolaemic, M
and F, mean 48 (SD 2) years
RCT, cross-over, LF diet (control) v. low-
dose pistachios v. high-dose pistachios,
no washout
32–63 g/d pistachios NS NS-EF; 20·10
63–126 g/d pistachios NS NS-EF; 0·10
M, male; F, female; RCT, randomised controlled trial; Med diet, Mediterranean diet; " , increase; þ , significant increase in endothelial function; Dm, type 2 diabetes mellitus; LA, linoleic acid; ALA, a-linolenic acid; NS, not significant;
NS-EF, no significant change in endothelial function; Met-S, metabolic syndrome; LF, low-fat.
* P,0·05.
† Vasodilator function measured by flow-mediated dilatation, except Lo´pez-Uriarte et al. (2010)(106), measured by Endo-PAT device.
‡ Mixed nuts ¼ walnuts, almonds and hazelnuts.
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observational studies; hence intervention studies are
important to isolate effects.
Significant reductions in blood pressure were observed
in nine intervention studies(46,47,58,67,76,82–84). Effect sizes
could be calculated in seven of these and were small to
large, ranging between 0·2 and 1·1. A substantial reduction
in systolic blood pressure (14 mmHg) was reported in par-
ticipants who were overweight or obese and mildly hyper-
tensive consuming a diet containing 84 g almonds/d for 24
weeks, compared with an isoenergetic high-carbohydrate
diet(76), with some participants reducing or eliminating
the use of antihypertensive medications during the dur-
ation of the study. A weight reduction of 7 % (BMI
reduction of 2·5 kg/m2) was also observed in the partici-
pants consuming nuts compared with the control, despite
the two groups being prescribed isoenergetic diets which
would have accounted for at least some of the reduction
in blood pressure observed(76). The PREDIMED Study
tested the consumption of a Mediterranean diet which
included 30 g mixed nuts/d compared with a Mediterra-
nean diet devoid of nuts(58). The study found a significant
reduction in systolic and diastolic blood pressure of 7 and 3
mmHg, respectively. This study used a large cohort of 772
participants; subgroups of this study with 49–106 partici-
pants also reported similar reductions in blood press-
ure(67,84,85). A larger cohort of the PREDIMED Trial found
only a significant reduction in diastolic blood pressure(83).
The NORDIET included nuts as part of the intervention
diet(46), and reductions were demonstrated in systolic and
diastolic blood pressure of 6 mmHg (effect size 0·6) and
2 mmHg (effect size 0·3), respectively. Almonds (23 g/d)
consumed of as part of a portfolio diet with plant sterols
and soya for 1 year demonstrated a reduction in systolic
and diastolic blood pressure in a single-phase prospective
study(82). However, as no control group was used, it is
possible that the regular clinic visits in this study increased
participant awareness of hypertension as a CVD risk factor
and other behaviour change may have contributed to the
reduction in blood pressure in addition to the almond
intervention(82); without a control group this could not
be determined. Consumption of a Mediterranean diet
including 20–50 g walnuts/d compared with a prudent
diet demonstrated reductions in systolic blood pressure
of 3 mmHg (effect size 0·7) and in diastolic blood pressure
of 2 mmHg (effect size 0·7)(47).
The majority of the remaining studies demonstrated
either small blood pressure reductions which did not
reach significance or no change. A reduction in systolic
and diastolic blood pressure was observed with con-
sumption of 40 g hazelnuts/d for 4 weeks from baseline;
however, this was not significantly different from the
reduction observed with cocoa used as the control(86).
Inclusion of a control food that is not likely to change
inflammation or endothelial function may have been a
better choice to determine the effects attributable to hazel-
nuts(87). An ad libitum diet with 56 g walnuts/d consumedTa
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Table 8. Effects of nut consumption on cognitive function
Author Time Subjects Study design Amount/type of nuts Outcomes
Effect;
effect size
Observational studies: effects of nut consumption on cognitive function
Valls-Pedret
et al.
(2012)(158)
X-sect n 447, risk of CVD, M and F,
mean 69 (range 55–80)
years
PREDIMED study, FFQ þ
cognitive battery
5 g/d (0–60 g) all nuts, 1 g/d
walnuts (0–30 g)
Walnuts (not other nuts) associated
with " working memory, r 1·2
(95 % CI 0·06, 2·32), b ¼ 0·15
(P¼0·04)
þ
Nooyens
et al.
(2011)(110)
5 years n 2613, general population,
range 43–70 years
The Doetinchem Prospective
Cohort Study, FFQ and
cognitive battery
Quintiles of any nut consump-
tion (amount not specified)
(1) " Nut intake associated with "
cognitive function (memory,
speed, flexibility and global)
(P-trend ,0·01)
þ
(2) " 5–8 years cognitive function
in high v. low nut consumers
(3) No # cognitive decline in nut
consumers over 5 years
Nurk et al.
(2010)(111)
X-sect n 2031, M and F, elderly, range
70–74 years
X-sect, FFQ þ cognitive battery Mean intake of nut
consumers ¼ 5 g/d
Nut intake associated with "
executive function, semantic
memory, NS
NS-CP
Chronic effects of nut consumption on cognitive function
Pribis et al.
(2012)(112)
8 weeks n 64, M and F, students, mean
21 (SD 2) years
RCT cross-over, banana bread
(control) with/without walnuts,
6 weeks washout
60 g/d walnuts Inferential verbal reasoning " 11 %
(d ¼ 0·6; P¼0·009)
þ ; 0·4
Mood, non-verbal reasoning and
memory, NS
NS-CP
X-sect, cross-sectional; M, male; F, female; PREDIMED, PREvencion con DIeta MEDiterranea; " , increase; þ , significant increase in cognitive performance; , decrease; NS, no significant change; NS-CP, no significant change in
cognitive performance; RCT, randomised controlled trial.
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by participants with type 2 diabetes for 8 weeks showed an
increase in systolic (effect size 20·8) and diastolic (effect
size 20·7) blood pressure. This unexpected result was
from the only study that demonstrated a significant
increase in blood pressure(72). The authors were not able
to determine a reason for this increase in blood pressure.
However, other factors in the diet such as Na consumption
may have contributed to the blood pressure elevation
(despite being prescribed unsalted nuts); Na intake was
not reported or controlled for in this study. Interventions
using a portfolio diet(88,89), NORDIET(46) or Mediterranean
diet(47,48) contained foods other than nuts which may also
have been beneficial for improvements in blood pressure,
making it difficult to tease out the effects of nuts alone. In
contrast, Mediterranean diets in which mixed nuts(58,67)
replaced olive oil demonstrated improvements in blood
pressure, indicating there may be some beneficial effect
of nuts above that of other components of the Mediterra-
nean diet. The largest effects of nuts on blood pressure
were seen in participants with the metabolic syndrome
or other risk factor for CVD, consuming 30–84 g of
almonds, walnuts or mixed nuts/d for 4 weeks to 2 years.
Significant reductions of 3–14 and 2–3 mmHg were
observed in systolic and diastolic blood pressure, respect-
ively(46,47,58,67,76,84,85). Only two of thirty-six studies
measured resting blood pressure as a primary outcome,
so the remaining studies may not have been powered to
detect small changes. In eight of the nine studies demon-
strating blood pressure reductions, nuts were consumed
for extended periods of between 12 weeks to 2 years.
Most studies demonstrated no beneficial effect on blood
pressure when nuts were consumed for shorter periods
(3–12 weeks). This suggests a benefit of nut consumption
only after an extended period of time as indicated with
observational studies where habitual nut consumption
was associated with reduced blood pressure or reduced
prevalence of hypertension.
Weighted mean changes in blood pressure were calcu-
lated for twenty-four of the thirty-six intervention studies;
systolic and diastolic pressure were significantly reduced
by 0·73 (95 % CI 21·3, 20·2) % and 0·75 (95 % CI 21·1,
0·4) %, respectively (see Table 9). Improvements in blood
pressure control were observed particularly when nuts
were consumed regularly for extended periods of time.
Although the effect of nut consumption on blood pressure
is small, this may still be clinically meaningful especially
when used with other lifestyle measures.
Effects of nut consumption on inflammatory markers
Studies measuring the effect of nut consumption on inflam-
matory markers are found in Table 5. The most commonly
measured inflammatory marker was CRP, reported in
twenty-seven of the thirty-one studies. Other inflammatory
markers measured included TNF-a, interleukins (IL-1,
IL-1b, IL-6, IL-7 and IL-18) and cellular adhesion molecules
(ICAM-1, VCAM-1 and E-selectin). We identified four cross-
sectional studies and twenty-seven intervention trials
measuring inflammatory markers with nut consumption.
Of the intervention studies, eleven compared nuts with a
healthy diet (low-fat or Mediterranean diet), five with a
Western, American or habitual diet, six studies compared
nut consumption with another food product (meat,
cocoa, lactose or olive oil), one study compared two
types of nut and one study was a single intervention
using pre- and post-measures with no control or compara-
tor food. The range of nuts used included almonds, wal-
nuts, mixed nuts, Brazil nuts, cashews, pistachios and
hazelnuts. The amounts ranged from 10 to 103 g (13 ounce
to 4 ounces) of nuts per d (approximately 5–25 % of
energy intake) for 4 weeks to 2 years. To date, only tree
nuts have been tested for effects on inflammatory markers
with chronic nut consumption.
In three of the four cross-sectional studies, nut consump-
tion was associated with lower concentrations of the
inflammatory markers CRP, IL-6 or ICAM. The Multi-
Ethnic Study of Atherosclerosis (MESA) demonstrated an
inverse association between frequency of consumption of
nuts and seeds and serum CRP and IL-6 levels(90). This
association was moderately attenuated by additional
adjustment for BMI. In two other studies, a Mediterranean
diet pattern (PREDIMED study) or an American diet includ-
ing nuts was inversely associated with anti-inflammatory
markers(91). Surprisingly, a large study (6309 women with
diabetes), which categorised the largest nut consumption
as $5 serves per week (1 serve ¼ 28 g nuts or 18 g
peanut butter) showed no association with inflammatory
markers(92).
A total of twelve intervention studies demonstrated
significant reductions (5–75 %) in inflammatory markers
with nut consumption with a variety of nuts. Consumption
of 21–100 g of walnuts, almonds, hazelnuts, pistachios
or mixed nuts per d for 4 weeks to 2 years in healthy
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Fig. 3. Number of studies measuring effects of nut consumption on glucore-
gulation, blood pressure, inflammation, endothelial function, arterial compli-
ance and cognition as epidemiological (B), uncontrolled (B) or randomised
controlled trials with primary (B) or secondary (A) outcomes.
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or hypercholesterolaemic participants or those at
high risk of CVD resulted in significant reductions of
CRP (5–75%)(47,84,86,88,89,93–95) or other inflammatory
markers (ICAM, VCAM, E-selectin and interleukins)
(7–28%)(47,58,59,84,93,95–98). A study incorporating walnuts
(37 g/d) plus walnut oil (15 g/d) or walnuts and walnut oil
plus flax seed as an additional source of ALA demonstrated
anti-inflammatory effects compared with an American
diet in hypercholesterolaemic individuals(93). The vascular
adhesion molecules ICAM-1, VCAM-1 as well as CRP
were all reduced significantly, with a dose–response
effect found for ALA in the diet with a 75 % reduction in
CRP. Participants who consumed 20–50 g walnuts/d for
2 years as part of a Mediterranean diet demonstrated a
reduction in CRP (36 %) and interleukins IL-6, IL-7 and
IL-18 (9–28 %) when compared with a prudent diet(47).
Mediterranean diets in which walnuts (about 65 g/d) or
mixed nuts (30 g/d) replaced olive oil demonstrated
improvements in one or more of the inflammatory markers
CRP, ICAM-1, VCAM-1 and IL-6(58,84,98). A reduction in CRP
was demonstrated in four studies with a portfolio diet con-
taining either almonds(89,94,99) (14–30 g/d) or hazelnuts
(30 g/d)(86) consumed for 4 weeks; one of these studies
found an reduction equivalent to that observed with
statin intake in the same individuals(89). Beneficial
improvements in inflammation observed in interventions
which contained foods in addition to nuts (portfolio
diet(88,89) or Mediterranean diet(47,48)) may have been
attributable to these other components. In contrast, Medi-
terranean diets in which walnuts(97), mixed nuts(58,67) or
pistachios(59) replaced olive oil demonstrated improve-
ments in one or more of the inflammatory markers CRP,
ICAM-1,VCAM-1 and IL-6, indicating that there may be
some beneficial effect of nuts above that of other com-
ponents of the Mediterranean diet. One study observed a
reduction in CRP with a portfolio diet containing almonds
only when participants with baseline CRP of # 3·5 mg/l
were excluded from analysis(94). (CRP levels $ 3·5 mg/l
reflect acute inflammation associated with infection or
acute illness that would mask any potential effects of nuts
on chronic inflammation.)(100) A 25 % reduction in IL-6
was observed with a relatively large dose (80–100 g/d) of
pistachios consumed for 4 weeks(59). Consumption of a
high-almond diet (68 g/d per 2000 kcal or 8368 kJ) and a
low-almond diet (34 g/d per 2000 kcal or 8368 kJ) for 4
weeks significantly decreased CRP compared with an
isoenergetic control diet in healthy men and women(95);
E-selectin (a marker of endothelial inflammation) was
significantly lower in the higher-almond group than con-
trol. No dose–response relationship was observed with
either inflammatory marker in this study. In participants
at risk of CVD, statistically significant reductions of the
cellular adhesion molecules ICAM-1 (effect size 0·3) and
VCAM-1 (effect size 0·4) were demonstrated with
relatively low doses (21 g/d) of walnuts added to a meat
product compared with the meat product without walnuts.T
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Despite little evidence for the magnitude of nut dose influ-
encing inflammation, it is possible that there is a minimum
dose required since no studies using , 30 g/d demon-
strated benefits.
In fifteen studies no significant changes in inflammatory
markers were demonstrated, although most of these
demonstrated small reductions. A recent three-arm study
compared fatty fish v. walnuts v. a fish-/nut-free diet (con-
trol). No significant changes were found between the
walnut and the control diets but E-selectin was reduced
with the walnut intervention compared with the fish
intervention(96). Consumption of 26 g almonds/d or 36 g
walnuts/d for 6 weeks led to a 19 % reduction in IL-6
with the almonds and 20 % reduction in TNF-a with the
walnuts compared with baseline, but this did not reach sig-
nificance. In addition, two studies with obese individuals
demonstrated small but non-significant improvements in
CRP(101) and IL-6(60) with Brazil nut and mixed nut con-
sumption, respectively. Suggested reasons for small but
non-significant reductions in inflammatory markers were
recruitment of healthy individuals who may only demon-
strate limited improvements and diurnal effects of IL-6
that are more difficult to detect than other markers. One
study with obese individuals demonstrated small but
non-significant improvements in CRP(101). Increased cen-
tral adiposity and body weight are associated with
increased CRP levels and adipose pro-inflammatory cyto-
kines including IL-6(102). It is possible that these individuals
may not demonstrate improvements in inflammatory mar-
kers with a dietary intervention without weight loss.
The calculated weighted mean changes for all studies
where data revealed reductions in ICAM-1, VCAM-1 and
CRP were 8·6 (95 % CI 220·5, 3·3) %, 5·8 (95 % CI 214·1,
2·5) % and 12 (95 % CI 223·6, 20·3) %, respectively (see
Table 9). In summary, nut consumption has the potential
to improve inflammatory markers, particularly with doses
of 30 g or greater. This is in line with a health claim for
nuts first established by the US Food and Drug Adminis-
tration (FDA) in 2003; scientific evidence suggests that
eating 42 g (1·5 ounces) of most nuts per d (as part of an
overall healthy diet) may be able to reduce the risk of
heart disease(103).
Effects of nut consumption on endothelial
vasodilator function
Studies measuring the effect of nut consumption on endo-
thelial vasodilator function are found in Table 6. In nine
intervention studies the effect of nut consumption on
endothelial vasodilator function (using either flow-
mediated dilatation or Endo-PAT device) was measured,
with the dose of nuts ranging from 10 to 100 g/d for
periods ranging from 4 to 12 weeks. Of the nine studies,
five demonstrated a significant effect.
Endothelial functionwassignificantly improved(24–64 %)
in healthy and hypercholesterolaemic participants who
consumed 37–100 g of walnuts or pistachios per d for
4–8 weeks(59,72,98,104). A Mediterranean diet supplemented
with 65 g walnuts/d substituted for olive oil significantly
improved vasodilation by 64 % in hypercholesterolaemic
adults(98). This study also demonstrated an inverse associ-
ation between vasodilation and cholesterol:HDL ratio,
suggesting that the effect of walnuts may have been
mediated in part through an improved lipid profile(98). It
is well established that hypercholesterolaemia impairs
endothelial function, which can be reversed by aggressive
cholesterol lowering(105). However, this study only demon-
strated moderate cholesterol lowering, indicating that other
mechanisms may also play a role. Investigators suggested
that phenolic compounds in walnuts may have counter-
acted the pro-oxidant effects of PUFA on LDL. Mediterra-
nean diets supplemented with 20–50 g walnuts/d(47) and
80–100 g pistachios/d(59) improved endothelial function
by 21 and 24 %, respectively. Also observed with pistachio
consumption was an improvement in glucose levels, lipid
parameters, oxidative status and some indices of inflam-
mation that may underlie the improved endothelial func-
tion(59). A diet with ad libitum consumption (56 g/d) of
walnuts improved endothelial function by 45 % (effect
size 0·6) in participants with type 2 diabetes(72). Consump-
tion of walnuts and walnut oil supplemented with flax seed
(to boost the ALA content of the diet) increased endothelial
function by 34 %, but no change was observed with the
walnut diet alone(104). Of the five studies using higher
doses (56–100 g/d) of nuts, four demonstrated benefits
on endothelial function, indicating that higher doses may
be required to elicit benefits(59,72,98,104).
Of the studies, four did not show significant effects on
flow-mediated dilatation. A hazelnut-enriched diet con-
sumed by healthy men improved lipid parameters. In
spite of this, endothelial functional improvement did not
reach statistical significance(74). A quantity of 10–30 g
nuts per d consumed by participants with either CVD
risk or the metabolic syndrome also demonstrated no ben-
efits on endothelial function(48,106). Consumption of two
doses (10 and 20 % of energy) of pistachios did not lead
to a reduction in endothelial function(107) despite relatively
high doses of up to 126 g/d consumed for 4 weeks.
The authors suggested that pistachios used were roasted
which may have reduced polyphenol activity unlike
walnuts used in other studies, which were not roasted
before consumption.
Calculations of the weighted mean changes from nine
of the ten studies indicated a 19·7 (95 % CI 4·3, 35·0) % rela-
tive increase in vasodilatation with nut consumption
(Table 9). The effects of nuts on endothelial function
demonstrate potential benefits, particularly walnuts. How-
ever, limited studies have been conducted with other
types of nuts that may also demonstrate benefits. Endo-
thelial dysfunction is often detected before increased
blood pressure is observed and may be a more sensitive
indicator than arterial compliance of early decline in
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vascular health; hence it may be a better target than blood
pressure control or arterial compliance(108).
Effects of nut consumption on arterial compliance
Studies measuring the effect of nut consumption on arterial
compliance are found in Table 7. These include one cross-
sectional study and one intervention study. A dose of 15 g
walnuts/d consumed for 4 weeks demonstrated no effect
on arterial stiffness(109). Whilst this dose is small, investi-
gators chose a realistic amount likely to be consumed in
free-living individuals for an extended period of time
rather than higher doses used in other nut intervention
studies. The cross-sectional study measured arterial com-
pliance and compared quintiles of a healthy dietary pattern
including nuts(52). No association was found between a
healthier diet pattern with an undetermined quantity of
nuts and measures of arterial compliance. Few studies
have investigated the effects of nuts on arterial compliance;
therefore more studies in this area are warranted.
Effects of nut consumption on cognitive performance
There is little known of the impact of nut consumption on
cognitive function. Studies measuring the effect of nut con-
sumption on cognitive performance are found in Table 8. A
5-year prospective cohort study demonstrated a positive
association between nut consumption and cognitive per-
formance, equivalent to a substantial age reduction effect
of 5–8 years in the highest-nut consumers (amount of
nuts not specified)(110). In addition, cognitive performance
did not decline over the 5-year period in the highest-nut
consumers. In a cross-sectional study (PREDIMED) an
association was found between walnut consumption (but
not other nuts) and improvements in performance on
tests of working memory (see Table 8). In older adults
nut consumption was associated with improved but non-
significant scores for executive function in a cross-sectional
study(111), with a low mean intake of nuts of 5 g/d. Only
one intervention study in human subjects has been per-
formed; this was conducted with students consuming
60 g ground walnuts/d for 8 weeks(112). The study demon-
strated a medium effect size (0·4) for improvement in infer-
ential reasoning; however, other cognitive tests demon-
strated no change. Despite the lack of intervention trials,
observational studies indicate that long-term consumption
of even small amounts of nuts may elicit benefits for cog-
nitive function and reduction in cognitive decline. More
evidence is needed from controlled intervention studies
before a conclusive benefit can be determined.
Proposed mechanisms
Several nutrients in nuts may be responsible for observed
improvements in cardiometabolic and cognitive measures.
Tree and ground nuts have similar nutrient profiles, with
some variations in micro- and macronutrients. From the
studies reviewed (with the exception of walnuts, which
have been more extensively researched than other nuts),
it is not possible to determine differences in efficacy
between different types of tree and ground nuts. Walnuts
differ from other nuts in their greater antioxidant capacity,
polyphenol and ALA content (see Table 1). ALA found in
walnuts is associated with improved endothelial func-
tion(31), inflammation(113) and neuroprotection in animal
models(114) and is hypothesised to maintain cognitive func-
tion in older adults(115). Other unsaturated fatty acids in
nuts may be beneficial for insulin sensitivity(116) and evi-
dence suggests that higher intakes are associated with a
lower risk of type 2 diabetes(117), whereas higher intakes
of SFA adversely affect glucose metabolism and insulin
resistance(118–120). There is also recent evidence to indicate
that MUFA may contribute to improvements in arterial stiff-
ness as well as endothelial function and inflam-
mation(121–124). Consumption of a Mediterranean diet that
is also high in MUFA has been shown to reduce VCAM-1
and E-selectin gene expression by almost half. Animal
and human studies have demonstrated that inflammation
can be modified by the intake of L-arginine(125). Individuals
with hypercholesterolaemia have impaired synthesis of
NO; supplementation of 7 g L-arginine/d in this population
group has demonstrated benefits(126), increasing endo-
thelial-dependent dilatation by almost 3·5-fold. Nuts con-
tain approximately 2–3 g arginine/100 g; hence doses of
30 g/d or more used in most studies could partly account
for the improvement in endothelial function observed.
Nuts also contain fibre and, when consumed with their
skin intact, contain a significant amount of polyphe-
nols(35,127), which have previously been shown to target
endothelial cells resulting in improved vascular func-
tion(42,128,129). Fibre intake can also increase insulin sensi-
tivity(130,131). Vitamin E found in nuts may have a role in
modifying some of the inflammatory mediators and may
be beneficial for cognitive performance(38,40). g-Toco-
pherol is a powerful antioxidant abundant in walnuts,
Brazil nuts and pistachios; however, its effect on markers
of cardiovascular risk including endothelial function and
inflammation has not yet been determined. Nuts are natu-
rally rich in K and Mg, which may facilitate blood pressure
reductions unless consumed in the salted form(132). In
addition, Mg, which has been inversely related to serum
CRP levels, has the potential to improve inflammation in
individuals with low Mg status(133) and Mg intake is inver-
sely associated with a reduced risk of type 2 diabetes(134).
There is emerging evidence that frequent nut consump-
tion beneficially affects cardiovascular risk beyond choles-
terol lowering. Key mechanisms include anti-inflammatory,
antioxidant and endothelial function, reduction in body fat
and improvement in glucose metabolism, which play a
central role in the development of atherosclerosis(135,136).
Endothelial function is essential for cerebral vascular
function to provide adequate cerebral blood flow to deliver
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nutrients (primarily glucose and oxygen) to the brain.
It has been hypothesised that by improving blood-flow
regulation in the brain, cognitive performance is also
improved(6,7). Nutritional interventions that have demon-
strated improvements in cerebral blood flow include n-3
fatty acids in fish oil(137), polyphenols in cocoa(138) and
wild green oats(139). Anti-inflammatory medications offer
some protection from Alzheimer’s disease, which is con-
sistent with the hypothesis that damage to brain cells is
part of an overall inflammatory reaction. If inflammation
is the key, then nuts which contain anti-inflammatory nutri-
ents, such as polyphenols, vitamin E and n-3 fatty acids
may prove to be important to reduce damage to the brain.
Conclusions
The results summarised in the present study provide evi-
dence that regular nut consumption may have a protective
effect on both vascular health and cognition. These ben-
efits were evident in trials with doses of higher intakes
(.30 g/d) for extended periods (several weeks or
longer). These findings further support the use of nuts to
reduce cardiometabolic dysfunction and highlight their
potential to maintain or restore endothelial function. This
in turn could improve cerebral blood flow and hence cog-
nitive performance as illustrated in Fig. 1. No published
studies to date have measured the effect of nut consump-
tion on cerebral blood flow and few studies have measured
the impact of nuts on arterial compliance and cognitive
performance. Whilst intervention studies have investigated
the impact of nuts on endothelial function, only one study
has taken the next step and considered whether nuts may
have beneficial effects on cognitive performance. Further
clinical studies are warranted to determine the type and
dose of nut and duration of consumption and which popu-
lations may benefit.
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